Metformin, rosiglitazone, or both for obese women with polycystic ovary syndrome?

Reflections
Published
Go to the profile of Fertility and Sterility
Fertility and Sterility
Editorial Office, American Society for Reproductive Medicine
Metformin, rosiglitazone, or both for obese women with polycystic ovary syndrome?
Like
Go to the profile of M. Blake Evans

Related Content

Fertility and Sterility
Fertility and Sterility Fertility and Sterility

Metformin, rosiglitazone, or both for obese women with polycystic ovary syndrome?

In this issue, Yujing et al. (1) compared the effects of the two most commonly used insulin sensitizers for obese, insulin resistant women with polycystic ovary syndrome (PCOS; by Rotterdam criteria). Two hundred four participants were randomized into three comparable groups. Group 1 received 1,500…

Volume 113, Issue 1, Pages 87–88

Authors:

Sushila Arya, M.D., Karl R. Hansen, M.D., Ph.D., Robert A. Wild, M.D., M.P.H., Ph.D.

Abstract:

Reflections on "Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial" by Li et al.


Read the full text here.

Go to the profile of Fertility and Sterility
Fertility and Sterility
Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. 

Please sign in or register for FREE

Your Fertility and Sterility Dialog login information is not the same as your ASRM or EES credentials. Users must create a separate account to comment or interact on the Dialog.

Sign In Register

Recommended Content